Target intelligence / Profile preview

Plakoglobin (JUP)

Target
JUP
Molecular classification
Catenin family protein, Cell adhesion molecule, Cytoplasmic plaque protein, Armadillo repeat protein
01

Overview

Plakoglobin (JUP) is a cytoplasmic protein found in both desmosomes and adherens junctions, serving as a critical component for "cell-cell adhesion" in cardiac muscle and epithelial tissues[1][3]. As a member of the catenin family, it anchors cadherins to the cytoskeleton and maintains tissue integrity[1][2]. JUP plays dynamic roles in regulating intercellular adhesion, tissue architecture, and multiple signaling pathways, such as Wnt/β-catenin and p53, with implications in both normal development and disease. Mutations or dysregulation of plakoglobin are linked to arrhythmogenic right ventricular dysplasia and several cancers. JUP functions as a potential diagnostic and prognostic biomarker and is being considered as a possible therapeutic target, particularly in oncology[2][3].

Other names
Junction plakoglobinγ-cateninCatenin gammaCTNNGDP3DPIIIPDGBPKGBdesmoplakin IIIdesmoplakin-3desmosomal protein 3junction plakoglobingamma-catenin
02

Mechanism of action

Not established for therapeutics; described mechanisms include potential modulation of signaling pathways (e.g., Wnt/β-catenin, p53, cadherin-mediated signaling) if hypothetical drugs target expression or function[2].

03

Biological functions

Cell-cell adhesionCytoskeletal organizationCell signaling (notably through Wnt/β-catenin and p53 pathways)Maintenance of tissue integrityRegulation of junctional complexes (desmosomes and adherens junctions)
04

Disease associations

CancerCardiovascular disease (notably arrhythmogenic right ventricular dysplasia, Naxos disease)Fibrosis
05

Safety considerations

Functionally critical for structural integrity of heart tissue—therapeutic targeting could risk cardiac dysfunction or arrhythmias[1][2]Dual roles in cancer: context-dependent pro-tumorigenic and tumor suppressor effects could pose challenges to safe targeting[2]
06

Interacting drugs

None established or approved; as of now, JUP is considered an investigational or emerging therapeutic target rather than the direct target of any approved drugs[2]
07

Biomarkers

JUP expression in tumors (prognostic and diagnostic marker in some cancers)Combined with CA125 for early diagnosis in certain contexts[2]

Beyond the preview

Go deeper on Plakoglobin (JUP).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Plakoglobin (JUP).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call